OneDigital Investment Advisors LLC Buys New Holdings in Natera, Inc. $NTRA

OneDigital Investment Advisors LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,696 shares of the medical research company’s stock, valued at approximately $460,000.

A number of other institutional investors have also recently bought and sold shares of the business. Horizon Investments LLC lifted its position in shares of Natera by 22.0% in the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock valued at $56,000 after buying an additional 44 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after acquiring an additional 47 shares during the last quarter. First Horizon Corp raised its stake in Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 51 shares during the period. Siemens Fonds Invest GmbH raised its stake in Natera by 3.1% in the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after acquiring an additional 54 shares during the period. Finally, Alamea Verwaltungs GmbH lifted its holdings in Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

NTRA opened at $325.07 on Thursday. The business has a fifty day simple moving average of $269.73 and a 200 day simple moving average of $228.01. The company has a market capitalization of $46.86 billion, a PE ratio of -239.02 and a beta of 1.51. Natera, Inc. has a 1 year low of $156.71 and a 1 year high of $326.03.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.74) EPS. Equities analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 478 shares of Natera stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the sale, the chief financial officer owned 51,637 shares in the company, valued at $14,159,898.14. The trade was a 0.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 295 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05. Following the completion of the sale, the insider directly owned 183,774 shares of the company’s stock, valued at $49,249,594.26. This represents a 0.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 181,045 shares of company stock worth $41,330,968. Insiders own 5.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on NTRA shares. Robert W. Baird set a $348.00 price objective on shares of Natera in a research report on Friday, August 7th. Guggenheim raised their target price on shares of Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Wells Fargo & Company raised their target price on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Evercore reissued an “outperform” rating and issued a $300.00 price target on shares of Natera in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus price target of $319.38.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.